ESG

Revealed: The medical devices companies leading the way in ESG

An analysis of thousands of records from GlobalData's proprietary themes, jobs, deals and patents databases reveals the most active medical device companies in the area of ESG.

Powered by 

Roche and GE are among the companies best positioned to take advantage of future ESG disruption in the medical devices industry, our analysis shows.

The assessment comes from GlobalData’s Thematic Research ecosystem, which ranks companies on a scale of one to five based on their likelihood to tackle challenges like ESG and emerge as long-term winners of the medical devices sector.

According to our analysis, Roche, GE and 3M are the companies best positioned to benefit from investments in ESG, all of them recording scores of five out of five in GlobalData’s Medical Devices Thematic Scorecard.

The table below shows how GlobalData analysts scored the biggest companies in the medical devices industry on their ESG performance, as well as the number of new ESG jobs, deals and patents from the companies since August 2021.

The final column in the table represents the overall score given to that company when it comes to their current ESG position relative to their peers. A score of five indicates that a company is a dominant player in this space, while companies that score less than three are vulnerable to being left behind. These can be read fairly straightforwardly.


The other data points in the table are more nuanced, showcasing recent ESG investment across a range of areas over the past year. These metrics, where available, give an indication of whether ESG is at the top of executives’ minds now, but high numbers in these fields are just as likely to represent desperate attempts to catch-up as they are genuine strength in ESG.


For example, a high number of deals could either indicate that a company is dominating the market, or that it is using mergers and acquisitions to fill in gaps in its offering.


This article is based on GlobalData research figures as of 26 August 2022. For more up-to-date figures, check the GlobalData website.

Go to article: Home | Robotic-powered prostheses – state of playGo to article: In this issueGo to article: ContentsGo to article: Formacoat Company InsightGo to article: FormacoatGo to article: Thermo Fisher Scientific Company InsightGo to article: Thermo Fisher ScientificGo to article: BriefingGo to article: Industry newsGo to article: The medical industry briefingGo to article: Alleima Company InsightGo to article: AlleimaGo to article: CommentGo to article: Global colonoscopy market set to exceed $4.4bn by 2030Go to article: Healthcare app regulators are missing the middleGo to article: Competitive dynamics in the orthopaedic robotics marketGo to article: Technimount SystemGo to article: LVL MedipharGo to article: In DepthGo to article: Can AI remedy the growing pains of digital biomarker development?Go to article: European companies poised to gain as EU Commission blocks Illumina-Grail dealGo to article: Youth mental health: can digital tools contain the crisis?Go to article: Robotic-powered prostheses – state of playGo to article: SartoriusGo to article: MelexisGo to article: In DataGo to article: Revealed: The medical devices companies leading the way in ESGGo to article: Revealed: The medical devices companies leading the way in cybersecurityGo to article: Declining healthtech innovation among medical industry Go to article: AccumoldGo to article: Repsol Go to article: EventsGo to article: Next Issue